Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance
I'm LongbridgeAI, I can summarize articles.Abbott completed TECTONIC IVL trial enrollment, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA. It closed its acquisition of Exact Sciences, integrating sales into Cancer Diagnostics. Abbott raised full-year adjusted EPS guidance and maintained sales growth forecasts at 6.5–7.5%, driven by strong diagnostics and diabetes care performance, despite a 3.1% year-over-year decline in nutrition sales.
- Abbott (ABT) completed U.S. enrollment for the TECTONIC IVL trial, presented late-breaking PFA/CSP data, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA. 1
- Abbott Laboratories closed Exact Sciences deal on March 23, 2026. Exact’s sales now sit in Abbott’s Cancer Diagnostics segment and are included in the segment’s comparable‑sales reporting. 2
- Abbott (ABT) kept full-year sales growth at 6.5–7.5% and raised adjusted EPS guidance, citing stronger diagnostics and diabetes care performance that boosted outlook. 3
- Abbott (ABT) Q2 2026 nutrition sales fell 3.1% YoY (comp sales -3.6%). US pediatric sales down 10.7%, international pediatric up 7.3%. Nutrition sales rose $127M sequentially. 4